Antibacterial agents active against Gram Negative Bacilli in phase I, II, or III clinical trials
“Antibacterial agents active against Gram‑Negative Bacilli in Phase I, II, or III Clinical Trials,” by David L. Paterson, surveys nearly 50 investigational therapeutics—28 small‑molecule antibiotics and 21 non‑traditional modalities—now in the clinic. The review highlights both the promise of this pipeline and the obstacles that remain, including toxicity‑related attrition, funding gaps for pivotal Phase III studies in high‑mortality indications such as ventilator‑associated pneumonia, and the developmental […]
This project has received funding from the European Union’s Horizon 2020 research and innovation programme under Grant Agreement No 966627 (OMNIX MEDICAL).